Biotech Recursion granted EU approval for rare disease  

Biotechnology company Recursion has been granted an Orphan Drug Designation for its potential treatment of the rare disease familial adenomatous polyposis (FAP).  

FAP is a rare tumour syndrome in which hundreds or thousands of precancerous colorectal polyps grow in the body. As it stands there are no approved therapies for the disease.  

Recursion’s therapy REC-4881 is an orally bioavailable non-ATP-competitive allosteric small molecule inhibitor of MEK1 and MEK2 being developed to reduce polyp burden and progression to adenocarcinoma in FAP patients. 

Now, the European Commission has granted REC-4881 Orphan Drug Designation.  

Official comments   

“FAP is a rare tumour syndrome that affects approximately 50,000 patients in the US, France, Germany, Italy, Spain and the UK, with no approved therapies”, said Meredith Brown-Tuttle, Vice President of Regulatory Affairs. “Recursion is excited about this Orphan Drug Designation in the European Union as we continue to advance towards initiating a Phase 2 clinical trial.” 

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free